HONG KONG, July 23, 2014 /PRNewswire-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, and Cordlife Group Limited ("Cordlife"), a multi-product healthcare company catering to the mother and child segment, today announced that the two companies have joined forces in assisting patients across the PRC, Singapore, Hong Kong, Indonesia, India, the Philippines and Malaysia to identify suitable cord blood matching units for stem cell therapy.
Under the Memorandum of Understanding signed between the two companies, Cordlife, on behalf of its patients who are in need of cord blood stem cell therapy, can facilitate the process by providing relevant information to CCBC, who will then perform searches for possible matching units among its donated cord blood samples in the PRC. For patients who reside in the PRC, CCBC may seek Cordlife's assistance or contacts to source possible cord blood unit matches in the relevant public cord blood registries in the regions where Cordlife operates, which include Hong Kong, Singapore, India, Indonesia, the Philippines, and Malaysia.
Mr. KAM Yuen, Chairman of China Cord Blood Corporation commented, "Both CCBC and Cordlife share a common vision which is to enhance people's lives through the widening of umbilical cord blood stem cells application services. Our proposed collaboration will assist families in the PRC and other pa
|SOURCE China Cord Blood Corporation|
Copyright©2014 PR Newswire.
All rights reserved